Phaarmasia Limited

PHRMASI6

INE486I01016

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:01:01 2024-07-05 EDT			5-day change	1st Jan Change
51.92 ^INR	-5.00%		-6.82%	+31.88%

05-25	Phaarmasia Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
05-25	Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Phaarmasia Limited Appoints Abhishek D. Wakchaure as the Company Secretary/Compliance Officer

August 11, 2016 at 06:57 am

Phaarmasia Limited appointed Mr. Abhishek D. Wakchaure as the Company Secretary/Compliance Officer of the company with the immediate effect from August 11, 2016.

Latest news about Phaarmasia Limited

Phaarmasia Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-25	CI
Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-25	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
Phaarmasia Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Phaarmasia Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-25	CI
Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-25	CI
Phaarmasia Limited Announces the Resignation of Maneesh Ramakant Sapte as Managing Director	23-03-31	CI
Maneesh Pharmaceuticals Limited canceled the acquisition of a 26.48658% stake in Phaarmasia Limited.	23-02-20	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Maneesh Pharmaceuticals Limited made an offer to acquire 26.48658% stake in Phaarmasia Limited for INR 45.2 million.	22-11-10	CI
Phaarmasia Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-10	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-09	CI
Phaarmasia Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-06	CI
Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-25	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-12	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-13	CI
Phaarmasia Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	20-09-15	CI
Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	20-06-30	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	20-02-13	CI
Phaarmasia Limited Announces Company Secretary and Compliance Changes	20-01-03	CI
Phaarmasia Limited Announces Executive Changes	19-12-05	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	19-11-14	CI

Phaarmasia Limited is an India-based company, which is primarily engaged in the manufacturing and sale of oral contraceptive pills (OCPâs). The Company manufactures and markets oral contraceptive tablets with various therapeutic dosage combinations along with iron tablets for the Ministry of Health & Family Welfare and for exports. Its product categories include hormone products and herbal products. Its hormone products include Estradiol Valerate Tablets; Medroxyprogesterone Acetate Tablets; Cabergoline Tablets; Clomiphene Citrate Tablets; Levonorgestrel Tablet; Fluoxymesterone tablets; Liothyronine Sodium tablets; Oxandrolone tablets and others. Its herbal products include Smyle Herbal Toothpaste; Smyle Cough & Sore Throat Reliver and Smyle Mouth Ulcer Gel. Its injectables include Testosterone Cypionate Injection; Methenolone Enanthate Injection; Drostanolone, Testosterone and Trenbolone Inj, and Stanozolol Cypionate Inj.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHAARMASIA LIMITED	+31.88%	4.25M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B